Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact ir@baincapital.com.
Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of DirectorsJnana initiates Phase 1 clinical trial of JNT-517, a potential first-in-class oral treatment for PKU; JNT-517 receives US FDA Rare Pediatric Disease DesignationBOSTON – Nov. 15, 2022 – Jnana Therapeutics ("Jnana"), a...
CHICAGO — November 3, 2022 — Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome. 'Bain Capital Life Sciences led the funding round with participation from Paragon Biosciences, Valor Equity Partners,...
Areteia will initiate Phase 3 trials of lead candidate, dexpramipexole, a potential first-in-class oral drug for eosinophilic asthma, in late 2022 Investors led by Bain Capital Life Sciences to invest up to $350 million in Series A financing Jorge Bartolome joins Areteia as CEO, bringing industry leadership experience in respiratory therapeuticsPITTSBURGH, PA & SHORT HILLS, NJ – July...
Beijing, San Francisco and Boston, December 8, 2021 – Avistone Pharmaceuticals (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced it has received a strategic investment of more than $200 million led by Vivo Capital with participation from Bain Capital and Primavera Capital (collectively the “Investor...
Boston, MA, October 27, 2021 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life...
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc. (NASDAQ: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.The financing...
CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced that it has closed a $260 million Series D financing led by D1 Capital Partners L.P. New investors HealthCor Investments LLC and Innovatus Capital Partners, LLC also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital,...
SAN DIEGO, June 9, 2021 /PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million financing tranche that brings the total Series D financing to more than $115 million. The financing includes participation by existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, as well as...
PHILADELPHIA, May 18, 2021 /PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing. The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences,...
In an interview with @carlosvaluto for the @IPEnews March issue, #RobinMarshall explained our approach to finding a… https://t.co/BeRdiYjr9c
Did you know: the first-ever @PanMass Challenge raised $10,000 with only 36 riders and 10 volunteers. Today, more t… https://t.co/SjNTBZMyaL
In recognition of the #BainCapitalDoubleImpact mission to support companies that improve educational outcomes, we a… https://t.co/nR6mhYZHOs
@newprofit is investing in 5 social impact organizations focused on transforming America's education and economic s… https://t.co/yKz2KVwvXY
Cecilia Chao and Davis Smith joined @FortuneMagazine's Leadership Next podcast to discuss the partnership between o… https://t.co/GuXFcqlkPR
Following the close of #BainCapitalTechOpportunties’ second fund, Darren Abrahamson expressed conviction in the cur… https://t.co/uro3pKq67U
After hitting multiple milestones over the last year, the close of two new #BainCapitalVentures funds reflects a hi… https://t.co/k5MLHLKQ0y
#BainCapitalPrivateEquity's @jp_connaughton and @ColinMotley held conversations to share their insights about priva… https://t.co/oyGjudeKbQ
In 2022, the Private Credit Group of #BainCapitalCredit invested $4B to support 120 high-quality businesses across… https://t.co/LH9YfZHQKH
We are proud to support @Cycle4Survival. Of the $319 million raised to date, every dollar has gone toward funding c… https://t.co/lcKNgk08YA